Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $30.00.

Several research analysts recently weighed in on KYTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. lowered their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new position in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $28,000. Legal & General Group Plc acquired a new stake in Kyverna Therapeutics in the 2nd quarter valued at approximately $36,000. Qube Research & Technologies Ltd acquired a new stake in Kyverna Therapeutics in the 2nd quarter valued at approximately $43,000. California State Teachers Retirement System purchased a new stake in Kyverna Therapeutics in the second quarter valued at approximately $46,000. Finally, Rhumbline Advisers raised its position in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the period. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

KYTX stock opened at $8.25 on Tuesday. Kyverna Therapeutics has a 1 year low of $3.60 and a 1 year high of $13.67. The firm has a market capitalization of $510.18 million, a PE ratio of -2.81 and a beta of 1.98. The business has a 50 day simple moving average of $8.19 and a 200-day simple moving average of $8.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 9.06 and a quick ratio of 9.06.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.05. Equities research analysts anticipate that Kyverna Therapeutics will post -2.7 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.